Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

NCT04742400 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

12

Enrollment

NIH

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: tolebrutinib 60mg
DRUG: tolebrutinib 120mg

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)